Related Experiment Video
Updated: Apr 25, 2026
Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
Fatty acid binding protein 4, resistin, diastolic dysfunction, and cardiovascular risk in patients with rheumatoid
Mariusz Ciołkiewicz1, Anna Kuryliszyn-Moskal1, Ewa Jabłońska2
1Department of Rehabilitation, Medical University of Bialystok, Bialystok, Poland.
Insights
Fatty acid binding protein 4 (FABP4) is linked to higher cardiovascular risk and diastolic dysfunction in rheumatoid arthritis (RA) patients. Lateral e' velocity is the best echocardiographic measure for assessing this risk in RA.
Area of Science:
- Cardiology
- Rheumatology
- Biomarkers
Background:
- Rheumatoid arthritis (RA) patients face elevated cardiovascular (CV) risk.
- Early detection of subclinical cardiac involvement is crucial for timely intervention.
- Fatty acid binding protein 4 (FABP4) and resistin are potential biomarkers for CV risk in RA.
Purpose of the Study:
- Evaluate associations between serum FABP4 and resistin levels with CV risk scores in RA patients.
- Assess relationships between FABP4 and resistin with echocardiographic parameters of left ventricular diastolic dysfunction (LVDD).
- Identify the most informative LVDD parameter for CV risk stratification in RA.
Main Methods:
- Fifty-one RA patients were enrolled.
- Serum FABP4 and resistin levels were measured.
- Associations with CV risk scores and LVDD parameters were analyzed using regression models.
Main Results:
- FABP4 showed a significant positive association with the ERS-RA CV risk score.
- FABP4 was associated with abnormal LVDD parameters, including E/A ratio and left atrial volume index.
- Lateral e' velocity demonstrated the strongest association with all CV risk scores among LVDD parameters.
Conclusions:
- Serum FABP4 is a significant biomarker associated with increased CV risk and LVDD in RA patients.
- Lateral e' velocity is the most informative echocardiographic parameter for CV risk stratification in RA.
- These findings support FABP4 and specific echocardiographic measures for improved CV risk assessment in RA.
Introduction:
Cardiovascular (CV) risk assessment and early detection of subclinical cardiac involvement in rheumatoid arthritis (RA) patients enable timely intervention and improve prognosis.
Objectives:
This study evaluated associations of serum levels of fatty acid binding protein 4 (FABP4) and resistin with both echocardiographic parameters of left ventricular diastolic dysfunction (LVDD) and CV risk quantified using four validated scores (ERS-RA, QRISK3, modified SCORE2, LIFE-CVD2) in a cohort of RA patients. Additionally, we sought to identify the most informative LVDD parameter for CV risk stratification.
Materials And Methods:
Fifty-one RA patients (46 females, 5 males; mean age 48.8± 8.2 years; median disease duration of 12 years) were enrolled. Serum FABP4 and resistin levels were analysed for associations with CV risk scores using univariable and multivariable linear regression, while relationships with LVDD parameters were assessed via univariable regression analyses.
Results:
FABP4 demonstrated a positive association with ERS-RA risk score in both univariable (β = 0.09, p = 0.01) and multivariable (β = 0.08, p = 0.007) models. FABP4 was negatively associated with E/A ratio (β = -0.005, p = 0.04), and positively with left atrial volume index (β = -0.09, p = 0.04). Among LVDD parameters, lateral e' velocity showed the strongest associations with all CV risk scores, exhibiting the lowest p-values.
Conclusions:
FABP4 is significantly associated with increased RA-specific CV risk (ERS-RA) and abnormal echocardiographic parameters of LVDD. Lateral e' velocity represents the most informative echocardiographic LVDD parameter associated with CV risk.
More Related Videos
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
07:44Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
Published on: July 14, 2023
Related Concept Videos
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
01:23Rheumatic Heart Disease I: Introduction
01:20Rheumatic Heart Disease IV: Nursing Management
01:26Atherosclerosis III: Management
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
01:38Inflammation